RXDX Ignyta Inc.

12.10
-0.30  -2%
Previous Close 12.40
Open 12.45
Price To book 5.93
Market Cap 680672372
Shares 56,253,915
Volume 469,807
Short Ratio 4.39
Av. Daily Volume 870,770

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171079095
  2. 8-K - Current report 171077992
  3. 8-K - Current report 171070237
  4. 8-K - Current report 171041501
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014747

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data update 2H 2017.
RXDX-105
Solid tumors - cancer
Ongoing.
Taladegib
Ovarian cancer
Phase 2 trial initiated September 2015. Updated data due 4Q 2017. NDA planned for 2H 2018.
STARTRK-2 entrectinib
Solid tumors - cancer

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171079095
  2. 8-K - Current report 171077992
  3. 8-K - Current report 171070237
  4. 8-K - Current report 171041501
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014747
  6. 8-K - Current report 171014621
  7. 8-K - Current report 17913540
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17897027
  9. 8-K - Current report 17895540
  10. CT ORDER - Confidential treatment order 17880023